Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 5, 2022 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the company has nominated a preclinical candidate (PCC)…

Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 6, 2022 /PRNewswire/ — Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the company has nominated a preclinical candidate (PCC)…

UVA College of Medication finds new data that may assist deal with cancers and microcephaly

CHARLOTTESVILLE, Virginia (WVIR) – UVA researchers found new genetic information that could help identify a contributor to microcephaly, a birth defect that affects the size of the brain. Doctor Noelle…

Personalised most cancers vaccines for breast, pancreatic cancers present promise – Washington College College of Medication in St. Louis

Visit the News Hub DNA vaccines target unique cancer mutations Getty Images Researchers at Washington University Medical School in St. Louis have shown that personalized cancer vaccines made with DNA…